Three Palm nets CE Mark for mammo software

TriMed Staff | | Health Imaging | Screening
Three Palm Software has received a CE Mark for its WorkstationOne and CadOne mammography software, which clears the company to market the products within 30 countries of the European Union (EU).

The Los Gatos, Calif.-based company said its WorkstationOne is diagnostic breast imaging workstation software that obtains breast imaging screening or diagnosis exams from PACS or modalities, and displays and manipulates the images for radiologists to perform interpretation. 

CadOne is a mammography CAD server, offered to original equipment manufacturers for integration into their product suites, according to Three Palm. CadOne is used in mammography screening, in particular, with digital data source (e.g., FFDM or CR for mammography).

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.